feedzop-word-mark-logo
searchLogin
Feedzop
homeFor YouIndiaIndia
You
bookmarksYour BookmarkshashtagYour Topics
Trending
Terms of UsePrivacy PolicyAboutJobsPartner With Us

© 2025 Advergame Technologies Pvt. Ltd. ("ATPL"). Gamezop ® & Quizzop ® are registered trademarks of ATPL.

Gamezop is a plug-and-play gaming platform that any app or website can integrate to bring casual gaming for its users. Gamezop also operates Quizzop, a quizzing platform, that digital products can add as a trivia section.

Over 5,000 products from more than 70 countries have integrated Gamezop and Quizzop. These include Amazon, Samsung Internet, Snap, Tata Play, AccuWeather, Paytm, Gulf News, and Branch.

Games and trivia increase user engagement significantly within all kinds of apps and websites, besides opening a new stream of advertising revenue. Gamezop and Quizzop take 30 minutes to integrate and can be used for free: both by the products integrating them and end users

Increase ad revenue and engagement on your app / website with games, quizzes, astrology, and cricket content. Visit: business.gamezop.com

Property Code: 5571

Home / Health / FDA Approves Home-Use Device for Depression Treatment

FDA Approves Home-Use Device for Depression Treatment

12 Dec

•

Summary

  • A new home-use device for depression treatment has been approved.
  • The device delivers gentle electrical currents to regulate mood.
  • It is intended for adults with moderate to severe depression.
FDA Approves Home-Use Device for Depression Treatment

Depression rates have significantly increased in the U.S., prompting the FDA to approve a new home-use device for treatment. Flow's FL-100 delivers a gentle electrical current to the brain's mood-regulating regions, offering a prescription-only option for adults aged 18 and older suffering from moderate to severe major depressive disorders. This innovative device can be used as a standalone treatment or alongside existing therapies.

The device is slated for a U.S. launch in the second quarter of 2026, with Flow's CEO targeting a retail price between $500 and $800. The company is actively negotiating insurance coverage partnerships, with announcements expected in early 2026. Globally, the FL-100 has already been utilized by over 55,000 individuals, with many reporting symptom improvement within weeks.

Clinical studies indicate that a substantial percentage of patients achieved remission after a 10-week treatment course. The typical treatment involves a 12-week regimen with daily sessions initially, tapering off over time. While generally mild, potential side effects include skin irritation and headaches, with rare instances of burns reported if device pads are reused or dried.

Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.
Flow's FL-100 is approved by the FDA for treating moderate to severe major depressive disorders in adults aged 18 and older.
The FL-100 delivers a gentle electrical current to the part of the brain that regulates mood, intended for home use under supervision.
Flow plans to launch the FL-100 device in the U.S. in the second quarter of 2026 as a prescription-only treatment.

Read more news on

Healthside-arrow
trending

Vaibhav Suryavanshi slams century

trending

KOSPI rises; Dow hits record

trending

Disney, OpenAI partner on Sora

trending

Nolan's 'Odyssey' stuns fans

trending

Suarez renewal with Inter Miami

trending

Single higher education regulator

trending

South Africa Women win series

trending

Delhi NCR GRAP-IV imposed

trending

December meteor shower in India

You may also like

ByHeart Formula: Years of Contamination Feared

11 Dec • 34 reads

article image

Botulism Spreads: All ByHeart Formula Linked to Sickness

11 Dec • 76 reads

article image

New Study: Gradual Tapering Cuts Relapse Risk

11 Dec • 9 reads

article image

Silent Crisis: Heavy Periods Cost NHS Millions

11 Dec • 17 reads

article image

Schools Reopen, Kids' Mental Health Soars!

10 Dec • 19 reads

article image